Antitubulin agents for the treatment of cancer - A medicinal chemistry update

Neeraj Mahindroo; Jing Ping Liou; Jang Yang Chang; Hsing Pang Hsieh

doi:10.1517/13543776.16.5.647

Antitubulin agents for the treatment of cancer - A medicinal chemistry update

Neeraj Mahindroo, Jing Ping Liou, Jang Yang Chang, Hsing Pang Hsieh

Research output: Contribution to journal › Review article › peer-review

80 Citations (Scopus)

Abstract

The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.

Original language	English
Pages (from-to)	647-691
Number of pages	45
Journal	Expert Opinion on Therapeutic Patents
Volume	16
Issue number	5
DOIs	https://doi.org/10.1517/13543776.16.5.647
Publication status	Published - 2006 May

All Science Journal Classification (ASJC) codes

Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/13543776.16.5.647

Cite this

@article{28edd79597b645a3b056c1ff7be78159,

title = "Antitubulin agents for the treatment of cancer - A medicinal chemistry update",

abstract = "The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.",

author = "Neeraj Mahindroo and Liou, {Jing Ping} and Chang, {Jang Yang} and Hsieh, {Hsing Pang}",

note = "Funding Information: The authors gratefully acknowledge National Health Research Institutes, Taiwan, Republic of China, for financial support, including NHRI postdoctoral fellowship to Neeraj Mahindroo.",

year = "2006",

month = may,

doi = "10.1517/13543776.16.5.647",

language = "English",

volume = "16",

pages = "647--691",

journal = "Expert Opinion on Therapeutic Patents",

issn = "1354-3776",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Antitubulin agents for the treatment of cancer - A medicinal chemistry update

AU - Mahindroo, Neeraj

AU - Liou, Jing Ping

AU - Chang, Jang Yang

AU - Hsieh, Hsing Pang

N1 - Funding Information: The authors gratefully acknowledge National Health Research Institutes, Taiwan, Republic of China, for financial support, including NHRI postdoctoral fellowship to Neeraj Mahindroo.

PY - 2006/5

Y1 - 2006/5

N2 - The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.

AB - The antitubulin agents taxanes and Vinca alkaloids form the first-line of treatment in clinical oncology for many cancers. The crucial role of microtubules in cell division has made antitubulin agents the focus of research, with sustained efforts to find new agents and to improve the profile of known agents by overcoming multi-drug resistance (MDR) and improving the druggability. The present review updates the medicinal chemistry of antitubulin agents covering the patents and literature published from May 2002 to November 2005. The antitubulin agents have been broadly classified into microtubule-destabilising agents, microtubule-stabilising agents and kinesin-like spindle protein inhibitors. This review provides an insight into the diversity of the chemical classes with antitubulin mechanisms of anticancer activity.

UR - http://www.scopus.com/inward/record.url?scp=33646551448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646551448&partnerID=8YFLogxK

U2 - 10.1517/13543776.16.5.647

DO - 10.1517/13543776.16.5.647

M3 - Review article

AN - SCOPUS:33646551448

SN - 1354-3776

VL - 16

SP - 647

EP - 691

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

IS - 5

ER -

Antitubulin agents for the treatment of cancer - A medicinal chemistry update

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this